Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01321385 |
Recruitment Status
:
Completed
First Posted
: March 23, 2011
Last Update Posted
: May 18, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
PURPOSE: This research trial is studying biomarkers in predicting response to treatment in bone marrow samples from young patients with acute myeloid leukemia.
Condition or disease | Intervention/treatment |
---|---|
Leukemia | Other: laboratory biomarker analysis Other: study of socioeconomic and demographic variables |
OBJECTIVES:
Primary
- To validate the accuracy of a pre-specified acute myeloid leukemia (AML) induction response classifier or the My Profile™ AML Induction Therapy Assay (run in a Good Laboratory Practice [GLP] laboratory using Good Manufacturing Practice [GMP] reagents) in predicting response to cytarabine-based induction chemotherapy in pediatric patients with non-M3 AML.
Secondary
- To validate the continuous score from the pre-specified induction response classifier as a predictor of response to induction chemotherapy, after controlling for the simultaneous effects of clinical variables at base-line and/or pre-induction therapy (e.g., age, WBC, and percentage [%] of blasts), and tests commonly available after the start of induction therapy (e.g., cytogenetics and molecular markers).
- To validate the accuracy of the pre-specified induction response classifier as a binary predictor of induction response using a pre-specified cutpoint to assign patients to no response (NR) or complete response (CR) groups.
- To validate the accuracy of the pre-specified induction response classifier as a binary predictor of induction response using a pre-specified cutpoint to assign patients to NR or CR groups, after controlling for the simultaneous effects of clinical variables at base-line (pre-induction therapy) (e.g., age, WBC, % blasts) and clinical variables, including tests commonly available after start of induction therapy (e.g., age, WBC, cytogenetics).
OUTLINE: Cryopreserved bone marrow mononuclear cell specimens are analyzed by cell networking profiling assays. Results are then compared with patient outcomes and demographics from COG-AAML03P1 and COG-AAML0531 studies.
Molecular markers analyzed include Flt3ITD, NPM1, CEBPA, and MRA.
Study Type : | Observational |
Estimated Enrollment : | 97 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Validation of a Classifier for Induction Response Prediction Using Single Cell Network Profiling (SCNP) Assays for Childhood AML |
Study Start Date : | March 2011 |
Actual Primary Completion Date : | May 2016 |

- Accuracy of induction response prediction
- Duration of complete response
- Event-free survival and overall survival
- Status (dead vs living)
- Date of last follow up
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
DISEASE CHARACTERISTICS:
-
Diagnosis of acute myeloid leukemia (AML)
- Non-M3 AML
-
Cryopreserved bone marrow mononuclear cell specimens from patients enrolled on COG-AAML03P1 and COG-AAML0531 collected prior to cytarabine-based induction therapy
- Patient samples from COG-AAML0531 must come from the control arm (i.e., no gemtuzumab ozogamicin induction therapy)
PATIENT CHARACTERISTICS:
- No Down syndrome
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01321385
Principal Investigator: | Norman J. Lacayo, MD | Stanford University |
Responsible Party: | Children's Oncology Group |
ClinicalTrials.gov Identifier: | NCT01321385 History of Changes |
Other Study ID Numbers: |
AAML11B8 COG-AAML11B8 ( Other Identifier: Children's Oncology Group ) NCI-2011-02851 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) AAML11B8 ( Other Identifier: Children's Oncology Group ) |
First Posted: | March 23, 2011 Key Record Dates |
Last Update Posted: | May 18, 2016 |
Last Verified: | May 2016 |
Keywords provided by Children's Oncology Group:
childhood acute myeloid leukemia in remission recurrent childhood acute myeloid leukemia untreated childhood acute myeloid leukemia and other myeloid malignancies childhood acute erythroleukemia (M6) childhood acute megakaryocytic leukemia (M7) childhood acute monoblastic leukemia (M5a) |
childhood acute monocytic leukemia (M5b) childhood acute myeloblastic leukemia with maturation (M2) childhood acute myeloblastic leukemia without maturation (M1) childhood acute myelomonocytic leukemia (M4) childhood acute minimally differentiated myeloid leukemia (M0) |
Additional relevant MeSH terms:
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms |